SynthesisClinical rheumatology2010
Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.
Synthesis in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 40 citations in OpenAlex.
- Case Report: Disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum.Frontiers in immunology · 2025Article
- Nationwide study on the prevalence of rheumatoid factor and anticitrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis.Turkish journal of medical sciences · 2024Article
- The Extracellular Vesicle Citrullinome and Signature in a Piglet Model of Neonatal Seizures.International journal of molecular sciences · 2023Article
- Putative Roles for Peptidylarginine Deiminases in COVID-19.International journal of molecular sciences · 2020Article
- Post-Translational Protein Deimination Signatures in Serum and Serum-Extracellular Vesicles ofInternational journal of molecular sciences · 2020Article
- Migratory Polyarthralgias and Skin Rash: Rat Bite Fever with a Positive Anti-Cyclic Citrullinated Peptide.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Poncet's Disease in the Preclinical Phase of Rheumatoid Arthritis.Case reports in rheumatology · 2018Article
- Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.The Journal of experimental medicine · 2016Review
- Arthritis and benznidazole: more closely related than we thought.Antimicrobial agents and chemotherapy · 2015Article
- Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease.Rheumatology international · 2014Article
- Antibodies to citrullinated peptides in tuberculosis.Clinical rheumatology · 2013Article
- Leprosy and rheumatoid arthritis: consequence or association?BMJ case reports · 2012Article
- Autoimmunity in Rheumatic Diseases Is Induced by Microbial Infections via Crossreactivity or Molecular Mimicry.Autoimmune diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a disease characterized by symmetrical polyarthritis of the large and small joints, and in the majority of patients, there is a presence of the rheumatoid factor and erosions in the X-ray of the joints. More recently, the presence of anti-cyclic citrullinated peptide antibodies (anti-CCP) in this disease has been described, with diagnostic and prognostic value. Nevertheless, these antibodies have also been described in infectious diseases. The aim of the present study was to make a systematic review of the presence of antibodies against citrullinated peptides in infectious diseases. Search was conducted in the MEDLINE (1966 to 2010), Cochrane, SCielo, and LILACS databases, using the terms: "anti-CCP, anti-MCV, and infectious diseases"; "anti-CCP, anti-MCV, and virus"; "anti-CCP, anti-MCV, and mycobacteria"; "anti-CCP, anti-MCV, and tuberculosis"; "anti-CCP, anti-MCV, and leprosy"; "anti-CCP, anti-MCV, and leishmaniasis"; "anti-CCP, anti-MCV, and HIV"; "anti-CCP and HTLV"; "anti-CCP, anti-MCV, and Chagas disease"; "anti-CCP, anti-MCV, and Lyme disease", and the corresponding terms in Portuguese. Twenty-five publications were found, which dealt with anti-CCP and infection, and only one on anti-MCV and infection. Of these, 23 were cross-sectional and three cohort studies. Anti-CCP antibodies were found in various frequencies, reaching 37% in tuberculosis. In the other infections, it was a rare finding. In only one publication, anti-MCV was found in only one patient with hepatitis. Since infectious diseases are capable of running their course with osteoarticular symptoms, sometimes difficult to differentiate from RA, additional studies are necessary to define the performance of the test for the detection of anti-CCP antibodies in populations in which the frequency of such infections is high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.